SCHEMBL3635876

SCHEMBL3635876

CCCC(=O)c1ccc(NCc2cnccc2C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FRK P42685 1/20 0.49
CAMK2B Q13554 1/20 0.49
CAMK2G Q13555 1/20 0.49
CAMK2D Q13557 1/20 0.49
NAMPT P43490 4/20 0.43
CYP2C9 P11712 1/20 0.43
HSD17B3 P37058 1/20 0.42
SOST Q9BQB4 1/20 0.40
SLC27A1 Q6PCB7 1/20 0.39
PIK3CA P42336 1/20 0.39
KDM4C Q9H3R0 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK1 P28482 2/20 0.39
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
MPI P34949 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3638458 0.82 SMN1; SMN2 (0.50) FRKCAMK2BCAMK2GCAMK2DSLC27A1
SCHEMBL3637367 0.80 SMN1; SMN2 (0.50) FRKCAMK2BCAMK2GCAMK2DHSD17B3
SCHEMBL3633186 0.80 HTT (0.51) FRKCAMK2BCAMK2GCAMK2DNAMPT
SCHEMBL3634267 0.78 ALDH1A1 (0.59) NAMPTALDH1A1POLBMAPTKMT2A
SCHEMBL3636193 0.77 HDAC6 (0.44) FRKCAMK2BCAMK2GCAMK2DCYP2C9
SCHEMBL3634550 0.76 HDAC1 (0.52) FRKCAMK2BCAMK2GCAMK2DHSD17B3
SCHEMBL3638178 0.75 FRK (0.47) FRKCAMK2BCAMK2GCAMK2DHSD17B3
SCHEMBL3634584 0.74 FRK (0.44) FRKCAMK2BCAMK2GCAMK2DNAMPT
SCHEMBL3634435 0.74 FRK (0.49) FRKCAMK2BCAMK2GCAMK2DHSD17B3
SCHEMBL3639533 0.74 FRK (0.46) FRKCAMK2BCAMK2GCAMK2DHSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 FRK 2372/4885CAMK2B 250/4885CAMK2G 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.